Related Experiment Video

Updated: Apr 30, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

New RAF kinase inhibitors in cancer therapy

Juan Martin-Liberal1, James Larkin

  • 1The Royal Marsden Hospital , Fulham Road SW3 6JJ, London , UK +44 20 7811 8576 ; +44 20 7811 8103 ; james.larkin@rmh.nhs.uk.

Expert Opinion on Pharmacotherapy
|April 29, 2014
PubMed
Abstract

Insights

BRAF inhibitors like vemurafenib and dabrafenib show success in BRAF-mutant melanoma. Dual BRAF-MEK inhibition appears superior, with BRAF mutation identification crucial for treatment success.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • BRAF pathway alterations are linked to various cancers.
  • BRAF inhibitors vemurafenib and dabrafenib are approved for BRAF-mutant advanced melanoma.

Purpose of the Study:

  • Review the efficacy and safety of vemurafenib and dabrafenib.
  • Examine emerging BRAF inhibitors and dual RAF-MEK inhibition strategies.
  • Provide a future outlook on MAPK pathway inhibition in cancer treatment.

Main Methods:

  • Literature review of antitumour activity and safety data.
  • Analysis of early clinical data for new BRAF inhibitors.
  • Evaluation of dual RAF-MEK inhibition therapeutic strategies.

Main Results:

  • BRAF inhibition has revolutionized BRAF-mutant melanoma treatment.
  • Efficacy of BRAF inhibitors in other malignancies is under investigation.
  • Dual BRAF-MEK inhibition shows promise, potentially exceeding single-agent therapy.

Conclusions:

  • Targeted BRAF inhibition is highly effective for specific melanoma patients.
  • Further research is needed to establish efficacy in broader cancer types.
  • Identifying specific BRAF mutations is critical for successful targeted therapy.
Keywords:
ERKMAPKMEKRAFRASdabrafenibmelanomatrametinibvemurafenib

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K